Clinical and molecular features of papillary thyroid cancer in adolescents and young adults

Menno R. Vriens, Willieford Moses, Julie Weng, Miao Peng, Ann Griffin, Archie Bleyer, Bradley H Pollock, Daniel J. Indelicato, Jimmy Hwang, Electron Kebebew

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Age disparities in thyroid cancer incidence and outcome among adolescents and young adults (AYAs) with thyroid cancer are under reported. In this study, the authors compared the molecular and clinical features of papillary thyroid cancer (PTC) in AYAs with the same features among patients in other age groups. Methods: One thousand eleven patients underwent initial treatment for PTC at the University of California at San Francisco. Patients were subdivided into 2 age groups: ages 15 to 39 years (the AYA group) and aged ≤40 years. Demographic, clinical, and survival data in the cohort also were compared with data from the National Cancer Instsitute's Surveillance, Epidemiology, and End Results (SEER) Program. In a subset of the study cohort, the primary tumors were analyzed by genome-wide expression analyses, genotyping for common somatic mutations, and pathway-specific gene expression arrays between the age groups. Results: The percentage of women and the lymph node metastasis rate were significantly higher in the AYA group. In the AYA group, the rate of distant metastasis was lower. Disease-free survival and median overall survival were significantly higher in the AYA group. The better survival in AYA patients also was apparent in the national SEER data. An unsupervised cluster analysis of gene expression data revealed no distinct clustering by age in 96 PTC samples. The frequency and type of somatic mutations in the primary tumors did not differ significantly between age groups (the AYA group vs the group aged ≤40 years). Six genes (extracellular matrix protein 1 [ECM1], v-erb-2 erythroblastic leukemia viral oncogene homolog 2 [ERBB2], urinary plasminogen activator [UPA], 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 [PFKFB2], meis homeobox 2 [MEIS2], and carbonic anhydrase II [CA2]) had significant differential expression between age groups. Conclusions: The extent of disease at presentation and the survival of patients with PTC differed between AYAs and older patients. The current results indicated that these differences may be caused by several candidate genes and that these genes are expressed differentially and may play an important role in tumor cell biology. However, no distinct gene expression profiles exist for patients with PTC that distinguish between AYAs and patients aged ≤40 years.

Original languageEnglish (US)
Pages (from-to)259-267
Number of pages9
JournalCancer
Volume117
Issue number2
DOIs
StatePublished - Jan 15 2011
Externally publishedYes

Fingerprint

Young Adult
Age Groups
Survival
Thyroid Neoplasms
Cluster Analysis
Neoplasms
Phosphofructokinase-2
Papillary Thyroid cancer
SEER Program
Carbonic Anhydrase II
Neoplasm Metastasis
Genes
Gene Expression
San Francisco
Homeobox Genes
Extracellular Matrix Proteins
Urokinase-Type Plasminogen Activator
Mutation Rate
Fructose
Oncogenes

Keywords

  • adolescents
  • genomics
  • oncogenes
  • thyroid cancer
  • young adults

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vriens, M. R., Moses, W., Weng, J., Peng, M., Griffin, A., Bleyer, A., ... Kebebew, E. (2011). Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer, 117(2), 259-267. https://doi.org/10.1002/cncr.25369

Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. / Vriens, Menno R.; Moses, Willieford; Weng, Julie; Peng, Miao; Griffin, Ann; Bleyer, Archie; Pollock, Bradley H; Indelicato, Daniel J.; Hwang, Jimmy; Kebebew, Electron.

In: Cancer, Vol. 117, No. 2, 15.01.2011, p. 259-267.

Research output: Contribution to journalArticle

Vriens, MR, Moses, W, Weng, J, Peng, M, Griffin, A, Bleyer, A, Pollock, BH, Indelicato, DJ, Hwang, J & Kebebew, E 2011, 'Clinical and molecular features of papillary thyroid cancer in adolescents and young adults', Cancer, vol. 117, no. 2, pp. 259-267. https://doi.org/10.1002/cncr.25369
Vriens MR, Moses W, Weng J, Peng M, Griffin A, Bleyer A et al. Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. Cancer. 2011 Jan 15;117(2):259-267. https://doi.org/10.1002/cncr.25369
Vriens, Menno R. ; Moses, Willieford ; Weng, Julie ; Peng, Miao ; Griffin, Ann ; Bleyer, Archie ; Pollock, Bradley H ; Indelicato, Daniel J. ; Hwang, Jimmy ; Kebebew, Electron. / Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. In: Cancer. 2011 ; Vol. 117, No. 2. pp. 259-267.
@article{a6d9912663444990b3162bbe070df510,
title = "Clinical and molecular features of papillary thyroid cancer in adolescents and young adults",
abstract = "Background: Age disparities in thyroid cancer incidence and outcome among adolescents and young adults (AYAs) with thyroid cancer are under reported. In this study, the authors compared the molecular and clinical features of papillary thyroid cancer (PTC) in AYAs with the same features among patients in other age groups. Methods: One thousand eleven patients underwent initial treatment for PTC at the University of California at San Francisco. Patients were subdivided into 2 age groups: ages 15 to 39 years (the AYA group) and aged ≤40 years. Demographic, clinical, and survival data in the cohort also were compared with data from the National Cancer Instsitute's Surveillance, Epidemiology, and End Results (SEER) Program. In a subset of the study cohort, the primary tumors were analyzed by genome-wide expression analyses, genotyping for common somatic mutations, and pathway-specific gene expression arrays between the age groups. Results: The percentage of women and the lymph node metastasis rate were significantly higher in the AYA group. In the AYA group, the rate of distant metastasis was lower. Disease-free survival and median overall survival were significantly higher in the AYA group. The better survival in AYA patients also was apparent in the national SEER data. An unsupervised cluster analysis of gene expression data revealed no distinct clustering by age in 96 PTC samples. The frequency and type of somatic mutations in the primary tumors did not differ significantly between age groups (the AYA group vs the group aged ≤40 years). Six genes (extracellular matrix protein 1 [ECM1], v-erb-2 erythroblastic leukemia viral oncogene homolog 2 [ERBB2], urinary plasminogen activator [UPA], 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 [PFKFB2], meis homeobox 2 [MEIS2], and carbonic anhydrase II [CA2]) had significant differential expression between age groups. Conclusions: The extent of disease at presentation and the survival of patients with PTC differed between AYAs and older patients. The current results indicated that these differences may be caused by several candidate genes and that these genes are expressed differentially and may play an important role in tumor cell biology. However, no distinct gene expression profiles exist for patients with PTC that distinguish between AYAs and patients aged ≤40 years.",
keywords = "adolescents, genomics, oncogenes, thyroid cancer, young adults",
author = "Vriens, {Menno R.} and Willieford Moses and Julie Weng and Miao Peng and Ann Griffin and Archie Bleyer and Pollock, {Bradley H} and Indelicato, {Daniel J.} and Jimmy Hwang and Electron Kebebew",
year = "2011",
month = "1",
day = "15",
doi = "10.1002/cncr.25369",
language = "English (US)",
volume = "117",
pages = "259--267",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical and molecular features of papillary thyroid cancer in adolescents and young adults

AU - Vriens, Menno R.

AU - Moses, Willieford

AU - Weng, Julie

AU - Peng, Miao

AU - Griffin, Ann

AU - Bleyer, Archie

AU - Pollock, Bradley H

AU - Indelicato, Daniel J.

AU - Hwang, Jimmy

AU - Kebebew, Electron

PY - 2011/1/15

Y1 - 2011/1/15

N2 - Background: Age disparities in thyroid cancer incidence and outcome among adolescents and young adults (AYAs) with thyroid cancer are under reported. In this study, the authors compared the molecular and clinical features of papillary thyroid cancer (PTC) in AYAs with the same features among patients in other age groups. Methods: One thousand eleven patients underwent initial treatment for PTC at the University of California at San Francisco. Patients were subdivided into 2 age groups: ages 15 to 39 years (the AYA group) and aged ≤40 years. Demographic, clinical, and survival data in the cohort also were compared with data from the National Cancer Instsitute's Surveillance, Epidemiology, and End Results (SEER) Program. In a subset of the study cohort, the primary tumors were analyzed by genome-wide expression analyses, genotyping for common somatic mutations, and pathway-specific gene expression arrays between the age groups. Results: The percentage of women and the lymph node metastasis rate were significantly higher in the AYA group. In the AYA group, the rate of distant metastasis was lower. Disease-free survival and median overall survival were significantly higher in the AYA group. The better survival in AYA patients also was apparent in the national SEER data. An unsupervised cluster analysis of gene expression data revealed no distinct clustering by age in 96 PTC samples. The frequency and type of somatic mutations in the primary tumors did not differ significantly between age groups (the AYA group vs the group aged ≤40 years). Six genes (extracellular matrix protein 1 [ECM1], v-erb-2 erythroblastic leukemia viral oncogene homolog 2 [ERBB2], urinary plasminogen activator [UPA], 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 [PFKFB2], meis homeobox 2 [MEIS2], and carbonic anhydrase II [CA2]) had significant differential expression between age groups. Conclusions: The extent of disease at presentation and the survival of patients with PTC differed between AYAs and older patients. The current results indicated that these differences may be caused by several candidate genes and that these genes are expressed differentially and may play an important role in tumor cell biology. However, no distinct gene expression profiles exist for patients with PTC that distinguish between AYAs and patients aged ≤40 years.

AB - Background: Age disparities in thyroid cancer incidence and outcome among adolescents and young adults (AYAs) with thyroid cancer are under reported. In this study, the authors compared the molecular and clinical features of papillary thyroid cancer (PTC) in AYAs with the same features among patients in other age groups. Methods: One thousand eleven patients underwent initial treatment for PTC at the University of California at San Francisco. Patients were subdivided into 2 age groups: ages 15 to 39 years (the AYA group) and aged ≤40 years. Demographic, clinical, and survival data in the cohort also were compared with data from the National Cancer Instsitute's Surveillance, Epidemiology, and End Results (SEER) Program. In a subset of the study cohort, the primary tumors were analyzed by genome-wide expression analyses, genotyping for common somatic mutations, and pathway-specific gene expression arrays between the age groups. Results: The percentage of women and the lymph node metastasis rate were significantly higher in the AYA group. In the AYA group, the rate of distant metastasis was lower. Disease-free survival and median overall survival were significantly higher in the AYA group. The better survival in AYA patients also was apparent in the national SEER data. An unsupervised cluster analysis of gene expression data revealed no distinct clustering by age in 96 PTC samples. The frequency and type of somatic mutations in the primary tumors did not differ significantly between age groups (the AYA group vs the group aged ≤40 years). Six genes (extracellular matrix protein 1 [ECM1], v-erb-2 erythroblastic leukemia viral oncogene homolog 2 [ERBB2], urinary plasminogen activator [UPA], 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 [PFKFB2], meis homeobox 2 [MEIS2], and carbonic anhydrase II [CA2]) had significant differential expression between age groups. Conclusions: The extent of disease at presentation and the survival of patients with PTC differed between AYAs and older patients. The current results indicated that these differences may be caused by several candidate genes and that these genes are expressed differentially and may play an important role in tumor cell biology. However, no distinct gene expression profiles exist for patients with PTC that distinguish between AYAs and patients aged ≤40 years.

KW - adolescents

KW - genomics

KW - oncogenes

KW - thyroid cancer

KW - young adults

UR - http://www.scopus.com/inward/record.url?scp=78650988256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650988256&partnerID=8YFLogxK

U2 - 10.1002/cncr.25369

DO - 10.1002/cncr.25369

M3 - Article

C2 - 20824721

AN - SCOPUS:78650988256

VL - 117

SP - 259

EP - 267

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -